Community Healthcare Trust heads into its May 6 earnings release with options markets flashing unusually bullish positioning — a sharp contrast to a stock that has spent most of the past year under pressure.
The clearest signal comes from the options market. The put/call ratio has collapsed to 0.25, the lowest reading of the past 52 weeks and more than one standard deviation below its 20-day average of 0.44. That means call volume is dominating to a degree that is historically rare for this name heading into a print. Price action supports the optimistic tilt: CHCT has rallied 10% over the past month to $17.64 and added a further 2.7% on Tuesday — a recovery that has brought the stock back toward the analyst consensus target of $18.50.
Short sellers are not pressing the bear case into the quarter. Short interest has fallen roughly 19% over the past month to 2.8% of the free float — a meaningful retreat from the mid-April peak above 3.3%. Borrow conditions remain easy, with cost to borrow running near 0.55% and the share availability ratio well above normal levels, indicating no squeeze pressure in the lending pool. The ORTEX short score of 34.9 places the stock comfortably in the lower half of the short-pressure universe.
The fundamental debate is where the real tension sits. Bulls point to a near-perfect EPS surprise record — the company ranks in the 98th percentile on that metric — alongside strong forward EPS momentum that ranks in the 89th percentile for year-on-year growth. A consistent pattern of quarterly dividend increases since the IPO also gives income-focused investors a reason to hold. Bears counter with a harsher picture on valuation: FFO estimates for 2026 have been cut to $2.00 per share, the stock trades at roughly 8.3x that figure against a historical average closer to 13x, and the implied discount to NAV is running at 34%. The most recent analyst moves — which date from February and March and are now stale for current trading purposes — showed Truist trimming its target to $19 while maintaining a Buy, and Piper Sandler nudging theirs up to $18 on a Neutral. The ratings haven't moved; only the price has, closing some of that gap. Mirae Asset added over 700,000 shares as recently as April, a material institutional commitment that suggests at least one sizeable buyer sees value near current levels.
Past prints have not been kind: the February 2026 release triggered a 5.5% single-day drop and a 6.7% five-day decline. The May report is therefore less about whether CHCT's portfolio can grow and more about whether management can demonstrate FFO recovery convincing enough to close the gap between an 8x multiple and a sector that has historically valued this business north of 13x.
See the live data behind this article on ORTEX.
Open CHCT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
